Aptose Biosciences (TSE:APS) Reaches New 1-Year Low - Here's Why

Key Points

• Aptose Biosciences shares reached a new **52-week low** of **C$1.72** during trading, down from the previous close of **C$2.05**.
• The company's **debt-to-equity ratio** stands at **-117.37**, indicating significant financial challenges, alongside a **PE ratio** of **-0.35**.
• Aptose is a **clinical-stage biotechnology** firm focused on developing personalized cancer therapies, with its lead program being **APTO-253**, currently in Phase I trials.

Aptose Biosciences Inc. (TSE:APS - Get Free Report) NASDAQ: APTO's stock price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$1.72 and last traded at C$1.72, with a volume of 16190 shares trading hands. The stock had previously closed at C$2.05.

Aptose Biosciences Stock Up 5.3%

The company has a debt-to-equity ratio of -117.37, a current ratio of 1.05 and a quick ratio of 5.41. The firm has a market cap of C$77.07 million, a PE ratio of -0.36 and a beta of 1.36. The company has a 50-day simple moving average of C$1.98 and a 200-day simple moving average of C$4.04.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.